Hikma Pharmaceuticals PLC (FRA:H5P)

Market Cap	4.14B -32.7%
Revenue (ttm)	2.74B +6.6%
Net Income	315.91M +30.2%
EPS	1.42 +31.2%
Shares Out	n/a
PE Ratio	13.11
Forward PE	9.56
Dividend	0.75 (4.00%)
Ex-Dividend Date	Aug 14, 2025

Volume	n/a
Average Volume	90
Open	18.80
Previous Close	18.70
Day's Range	18.70 - 18.80
52-Week Range	17.20 - 28.00
Beta	n/a
RSI	59.48
Earnings Date	Feb 26, 2026

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and specialty products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company...

• Industry: Pharmaceutical Preparations
• Founded: 1978
• Employees: 9,500
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: H5P

Financial Performance

In 2024, Hikma Pharmaceuticals's revenue was $3.13 billion, an increase of 8.77% compared to the previous year's $2.88 billion. Earnings were $359.00 million, an increase of 88.95%.

Financial numbers in USD